|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||22.11 - 22.85|
|52 Week Range||9.03 - 24.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2017 - Mar 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.50|
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / U.S. equities plunged on Friday as rising currency crisis in Turkey fueled a global market pullback. The Turkish lira is down 20 percent this week, slumping ...
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of -16.67% and -13.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Henderson, Nevada-based company said it had profit of 13 cents. Losses, adjusted for one-time gains and costs, came to 21 cents per share. The biotechnology company posted revenue ...
HENDERSON, Nev.-- -- An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent conversations with the FDA Both Phase 3 ROLONTIS ® studies, RECOVER and ADVANCE, ...
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the second quarter 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, August 9, ...
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICU ...
LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed data from the ADVANCE Phase 3 study which showed that ROLONTIS had an absolute risk reduction of severe neutropenia of 8.5 percent (95% CI: 0.2%, 16.2%) versus pegfilgrastim in Cycle 1. New safety data presented today also showed that the adverse events were not significantly different between two treatment arms.
Here are four stocks in biotech, energy and media that are breaking out on news. Endocyte Inc.(ECYT) had a strong session Tuesday, up 81 cents, or 6%, to $14.45 on 1.4 million shares traded. The biopharmaceutical company, which on Monday was added to the Russell 3000 Index, announced that an image from its Phase 2 prostate cancer study was selected as “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Spectrum Pharmaceuticals saw its shares rise after a Bloomberg report revealed that the hematology and oncology company may be considering a sale. Shares of Sophiris Bio were bouncing in Tuesday trading after plummeting on Monday when Wall Street learned that a patient had died in the company’s ongoing phase 2b clinical trial for its prostate drug topsalysin. Spectrum Pharmaceuticals, Inc. shares closed up 14.59% on about 6.4 million shares traded yesterday.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Achieve Life Sciences Inc (NASDAQ: ACHV ) stock was ...
LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.
Spectrum Pharmaceuticals Inc., a U.S. biotech company focused on oncology and hematology, is exploring options including a sale of the business amid takeover interest from other drugmakers, people familiar ...
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday, June 29th at 8:30 a.m. EDT/5:30 a.m. PDT to discuss the ROLONTIS Phase 3 ADVANCE study data being presented at Multinational Association of Supportive Care in Cancer (MASCC) 2018 annual meeting. The call will feature a presentation from ADVANCE study lead investigator, Lee S. Schwartzberg, M.D., FACP Professor of Medicine and Division Chief, Hematology Oncology, The University of Tennessee Health Science Center, and Executive Director, UT/West Cancer Center.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), with a market capitalization of US$2.06B, rarely draw their attention from the investingRead More...
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / U.S. equities closed in the green on Wednesday, as bond yields rose pushing financial sector higher. The Dow Jones Industrial Average jumped 1.40 percent to close ...
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 Global Healthcare Conference being held at the Grand Hyatt in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).
Fourth paragraph, first sentence of release dated May 16, 2018, should read: “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients” (instead of “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes two Phase 3 clinical studies involving approximately 800 patients”). ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy.